Search Result

Results for "

STAT3+activator

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (4) Bcl-2 Family (3) c-Myc (1) CDK (1) CXCR (1) Drug Metabolite (1) Endogenous Metabolite (5) Ephrin Receptor (3) Ferroptosis (1) FGFR (1) Fungal (1) Glutathione Peroxidase (1) Histone Acetyltransferase (2) Histone Demethylase (1) Histone Methyltransferase (1) HSP (1) Interleukin Related (3) Isotope-Labeled Compounds (1) JAK (1) Necroptosis (1) PPAR (1) Prostaglandin Receptor (1) Reactive Oxygen Species (ROS) (1) Reference Standards (4) SARS-CoV (1) Ser/Thr Kinase (1) STAT (19) Survivin (2) UGT (2)
By Research Areas:	Cancer (23) Cardiovascular Disease (3) Endocrinology (1) Infection (4) Inflammation/Immunology (5) Metabolic Disease (3)

By Targets:

Apoptosis (4)

Bcl-2 Family (3)

c-Myc (1)

CDK (1)

CXCR (1)

Drug Metabolite (1)

Endogenous Metabolite (5)

Ephrin Receptor (3)

Ferroptosis (1)

FGFR (1)

Fungal (1)

Glutathione Peroxidase (1)

Histone Acetyltransferase (2)

Histone Demethylase (1)

Histone Methyltransferase (1)

HSP (1)

Interleukin Related (3)

Isotope-Labeled Compounds (1)

JAK (1)

Necroptosis (1)

PPAR (1)

Prostaglandin Receptor (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (4)

SARS-CoV (1)

Ser/Thr Kinase (1)

STAT (19)

Survivin (2)

UGT (2)

By Research Areas:

Cancer (23)

Cardiovascular Disease (3)

Endocrinology (1)

Infection (4)

Inflammation/Immunology (5)

Metabolic Disease (3)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113261

Oleoylcarnitine	Endogenous Metabolite	Metabolic Disease Cancer
Oleoylcarnitine, the metabolite which accumulates through suppression of fatty acid β-oxidation, can enhance hepatocarcinogenesis via *STAT3* activation .

HY-N0897

Corylifol A 4 Publications Verification Corylifol-A; Corylinin	UGT STAT	Others
Corylifol A inhibits IL-6-induced *STAT3* activation and phosphorylation, with an IC₅₀ of 0.81 μM.

HY-100671

L002	Histone Acetyltransferase STAT	Cardiovascular Disease Inflammation/Immunology Cancer
L002 is a potent, cell permeable, reversible and specific acetyltransferase p300 (KAT3B) inhibitor with an IC₅₀ of 1.98 μM . L002 binds the acetyl-CoA pocket and competitively inhibits the FATp300 catalytic domain, blocks histone acetylation and p53 acetylation, and inhibits STAT3 activation . L002 has the potential for hypertension-induced cardiac hypertrophy and fibrogenesis treatment ^[3].

HY-113205

15-keto-Prostaglandin E2 15-keto-PGE2	Endogenous Metabolite Prostaglandin Receptor STAT PPAR Fungal Drug Metabolite	Cardiovascular Disease Infection Endocrinology Cancer
15-keto-Prostaglandin E2 (15-keto-PGE2) is an endogenous PGE₂ metabolite. 15-keto-Prostaglandin E2 inhibits STAT3 activation by binding to the Cys259 residue of *STAT3. 15-keto-Prostaglandin E2 binds to and stabilizes EP2* and EP4 receptors. 15-keto-Prostaglandin E2 inhibits the growth and progression of breast cancer cells. 15-keto-Prostaglandin E2 activates PPAR-γ and promotes fungal growth. 15-keto-Prostaglandin E2 disrupts glomerular vascularization during zebrafish development and reduces the surface area of the glomerular filtration barrier ^[3].

HY-112338

C188 CPD188	STAT Apoptosis	Cancer
C188 (CPD188) is a *STAT3* inhibitor with anticancer effects. C188 inhibits STAT3 SH2/pY-peptide binding (IC₅₀ of 20 µM against pY-peptide binding) and IL-6-mediated STAT3 phosphorylation. C188 is selective for STAT3 over STAT1. C188 inhibits nuclear-to-cytoplasmic translocation of Stat3. C188 shows highly active induces apoptosis in breast cancer cell lines with constitutive Stat3 activation (EC₅₀s of 0.73 µM, 3.96 µM, and 7.01 µM in MDA-MB-468, MDA-MB-231, and MDA-MB-435 cultures, respectively) .

HY-162275

JMJD1C-IN-1	Histone Demethylase Histone Methyltransferase STAT	Cancer
JMJD1C-IN-1 is an orally active and selective inhibitor of JMJD1C (IC₅₀ = 0.59 μM, K_d = 1.96 μM). JMJD1C-IN-1 inhibits the binding of JMJD1C to H3K9me2 peptide substrate in the HTRF assay (IC₅₀ = 1.47 μM). JMJD1C-IN-1 disrupts intratumoral regulatory T (Treg) cell fitness by dual mechanisms: promoting *H3K9me2* accumulation to downregulate PD1 expression and reducing *STAT3* demethylation to enhance *STAT3* activation. JMJD1C-IN-1 demonstrates dose-dependent antitumor efficacy in multiple mouse tumor models (MCA205 fibrosarcoma, B16-F10 melanoma, LLC lung cancer, Hepa1-6 hepatocellular carcinoma, CT26 colorectal cancer). JMJD1C-IN-1 can be used for the study of tumor immunotherapy by selectively targeting intratumoral Treg cells .

HY-107460

LDN-211904 oxalate 1 Publications Verification	Ephrin Receptor	Cancer
LDN-211904 oxalate is a potent and reversible *EphB3* inhibitor with an IC₅₀ of 79 nM. LDN-211904 oxalate shows good metabolic stability in mouse liver microsomes. LDN-211904 oxalate with Cetuximab (HY-P9905) could be effective in inhibiting STAT3-activated colorectal cancer (CRC) stemness and Cetuximab resistance in CRC .

HY-112391

SD-1029 1 Publications Verification	JAK STAT	Cancer
SD-1029 is a *JAK2/STAT3* inhibitor . SD-1029 inhibits STAT3 nuclear translocation. SD-1029 is an inhibitor of STAT3 activation due to inhibition of JAK2 phosphorylation .

HY-P2282

APTSTAT3-9R 1 Publications Verification	STAT	Cancer
APTSTAT3-9R, a specific STAT3-binding peptide, inhibits STAT3 activation and downstream signaling by specifically blocking *STAT3* phosphorylation. APTSTAT3-9R exerts antiproliferative effects and antitumor activity .

HY-N8146

Bruceantinol	STAT Bcl-2 Family Ser/Thr Kinase Survivin c-Myc Apoptosis Necroptosis CDK	Infection Cancer
Bruceantinol is a quassinoid that can be isolated from Brucea javanica, inhibits pepper mottle virus (PepMoV) in pepper. Bruceantinol is a *STAT3* inhibitor demonstrating potent antitumor activity in in vitro and in vivo human colorectal cancer (CRC) models. Bruceantinol has potent anti-leukemic activity. Bruceantinol strongly inhibits STAT3 DNA-binding ability (IC₅₀ = 2.4 pM), blocks the constitutive and IL-6-induced STAT3 activation, and suppresses transcription of MCL-1, PTTG1, survivin and c-Myc. Bruceantinol binds with CDK2/4/6 to facilitate protein degradation through proteasome pathway. Bruceantinol can dose- and time-dependently reduces the cell growth, impede cell proliferation, disrupts the cell cycle, and induces necrosis in MCF-7 cells and apoptosis in MDA-MB-231 cells ^[3].

HY-126421

Kansuinine A	Interleukin Related	Infection Cancer
Kansuinine A inhibits IL-6-induced Stat3 activation. Kansuinine A possesses antiviral and anticancer activity .

HY-N3255

Minecoside	CXCR STAT	Inflammation/Immunology Cancer
Minecoside is a *CXCR4/STAT3* inhibitor with anticancer and anti-inflammatory activity. Minecoside decreases CXCR4 expression and suppresses STAT3 activation, thus to inhibit CXCL 12-induced invasion. Minecoside potently inhibits cancer metastasis and promotes apoptotic progression .

HY-147187

MNK8	STAT Apoptosis Bcl-2 Family Survivin	Cancer
MNK8 is a potent *STAT3* (signal transducer and activator of transcription 3) inhibitor. MNK8 inhibits STAT3 activation and reduced its DNA binding ability. MNK8 shows good growth inhibition against hepatocellular carcinoma (HCC) cells. MNK8 induces apoptosis in HCC cells. MNK8 reduces prosurvival proteins expression and migration/invasion of HCC cells .

HY-118618

Eucannabinolide Hiyodorilactone A; Schkuhrin I	STAT	Cancer
Eucannabinolide is a *STAT3* inhibitor. Eucannabinolide suppresses STAT3 activation at tyrosine 705, inhibiteds its translocation to nucleus, and decreases its DNA binding capacity. Eucannabinolide can be used for triple negative breast cancer (TNBC) diseases research .

HY-167692

JI069	STAT	Others
JI069 is a novel JAK-STAT inhibitor that demonstrates potent activity in suppressing Th1, Th2, and Th17 differentiation while promoting iTreg differentiation. JI069 effectively inhibits STAT3 activation as well as the activation of other STATs, including STAT1, STAT5, and STAT6. JI069 has shown significant therapeutic potential in alleviating symptoms of collagen-induced arthritis in mice while inhibiting cytokine production from T cells and the phosphorylation of STAT3 in synovial cells.

HY-113261S

Oleoylcarnitine-d9	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease Cancer
Oleoylcarnitine-d₉ is deuterium labeled Oleoylcarnitine. Oleoylcarnitine, the metabolite which accumulates through suppression of fatty acid β-oxidation, can enhance hepatocarcinogenesis via *STAT3* activation .

HY-136358

LDN-211904	Ephrin Receptor	Cancer
LDN-211904 is a potent and reversible *EphB3* inhibitor with an IC₅₀ of 79 nM. LDN-211904 shows good metabolic stability in mouse liver microsomes. LDN-211904 with cetuximab could be effective in inhibiting STAT3-activated colorectal cancer (CRC) stemness and Cetuximab (HY-P9905) resistance in CRC .

HY-126420

Kansuinine B	SARS-CoV Interleukin Related	Infection Inflammation/Immunology
Kansuinine B inhibits IL-6-induced Stat3 activation. Kansuinine B possesses anti-viral activity and could be used in the study for COVID-19 ^[3].

HY-163176

WB518	STAT	Inflammation/Immunology
WB518 is a potent *STAT3* inhibitor. WB518 effectively inhibits STAT3 activation and Keratin 17 expression. WB518 effectively alleviates imiquimod (HY-B0180) and TPA (HY-18739)-induced animal psoriasis by inhibiting STAT3 phosphorylation and Keratin 17 .

HY-162605

CYD0682	STAT HSP	Cancer
CYD0682 is an analog of Oridonin (HY-N0004). CYD0682 attenuates *STAT3* activation and ECM production via an HSP90 pathway in hepatic stellate cells .

HY-N0897R

Corylifol A (Standard) Corylifol-A (Standard); Corylinin (Standard)	UGT Reference Standards STAT	Others
Corylifol A (Standard) is the analytical standard of Corylifol A. This product is intended for research and analytical applications. Corylifol A inhibits IL-6-induced STAT3 activation and phosphorylation, with an IC₅₀ of 0.81 μM.

HY-113261R

Oleoylcarnitine (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease Cancer
Oleoylcarnitine (Standard) is the analytical standard of Oleoylcarnitine. This product is intended for research and analytical applications. Oleoylcarnitine, the metabolite which accumulates through suppression of fatty acid β-oxidation, can enhance hepatocarcinogenesis via STAT3 activation .

HY-178140

STAT3-IN-47	STAT	Cancer
STAT3-IN-47 is an orally active *STAT3* inhibitor. STAT3-IN-47 exhibits broad-spectrum anti-tumor activity against HeLa, HepG2, U87, and LN229 cells. STAT3-IN-47 suppresses *STAT3* activation in vitro. STAT3-IN-47 can be used for the study of solid tumors, especially central nervous system (CNS) malignancies and hepatocellular carcinoma .

HY-E70717

FGFR1 V561M Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR1 has been implicated in numerous cancer types including non-small cell lung cancer (NSCLC). FGFR1 is activated upon FGF binding to its extracellular domain, resulting in protein dimerization and transautophosphorylation of the intracellular tyrosine kinase domains. FGFR1 V561M gatekeeper mutation drives Fexagratinib (AZD4547) (HY-13330) resistance through STAT3 Activation and EMT. FGFR1 V561M Recombinant Human Active Protein Kinase is a recombinant FGFR1 V561M protein that can be used to study FGFR1 V561M-related functions .

HY-107460R

LDN-211904 oxalate (Standard)	Reference Standards Ephrin Receptor	Cancer
LDN-211904 oxalate (Standard) is the analytical standard of LDN-211904 (oxalate) (HY-107460). This product is intended for research and analytical applications. LDN-211904 oxalate is a potent and reversible EphB3 inhibitor with an IC₅₀ of 79 nM. LDN-211904 oxalate shows good metabolic stability in mouse liver microsomes. LDN-211904 oxalate with Cetuximab (HY-P9905) could be effective in inhibiting STAT3-activated colorectal cancer (CRC) stemness and Cetuximab resistance in CRC .

HY-N18989

Cyclo(L-Ile-D-Leu)	STAT Interleukin Related Endogenous Metabolite	Cancer
Cyclo (L-Ile-D-Leu) (Compound 15) is a *STAT3* inhibitor. Cyclo (L-Ile-D-Leu) is isolated from the culture broth of Lactococcus lactis KR-050L. Cyclo (L-Ile-D-Leu) inhibits IL-6-induced *STAT3* activation in cancer cells. Cyclo (L-Ile-D-Leu) is applicable to hepatocellular carcinoma research .

HY-100671R

L002 (Standard)	Histone Acetyltransferase Reference Standards STAT	Cardiovascular Disease Inflammation/Immunology Cancer
L002 (Standard) is the analytical standard of L002 (HY-100671). This product is intended for research and analytical applications. L002 is a potent, cell permeable, reversible and specific acetyltransferase p300 (KAT3B) inhibitor with an IC50 of 1.98 μM . L002 binds the acetyl-CoA pocket and competitively inhibits the FATp300 catalytic domain, blocks histone acetylation and p53 acetylation, and inhibits STAT3 activation . L002 has the potential for hypertension-induced cardiac hypertrophy and fibrogenesis treatment ^[3].

HY-180245

STAT3-IN-51	STAT Ferroptosis Apoptosis Glutathione Peroxidase Bcl-2 Family Reactive Oxygen Species (ROS)	Cancer
STAT3-IN-51 is a *STAT3* inhibitor that directly binds to the STAT3 SH2 domain. STAT3-IN-51 induces apoptosis, ferroptosis, and immunogenic cell death (ICD) to potentiate anti-tumor immunity. STAT3-IN-51 inhibits STAT3 activation (phosphorylation, p-STAT3) and its downstream signaling. STAT3-IN-51 induces ROS generation, decreases Bcl-2 expression, disruptes mitochondrial function, suppresses GPX4 activity, and promotes lipid peroxidation. STAT3-IN-51 can be used for the study of colorectal carcinoma, breast adenocarcinoma, non-small cell lung cancer (NSCLC) and Cisplatin (HY-17394)-resistant pulmonary adenocarcinoma .

Cat. No.	Product Name	Target	Research Area